{"brief_title": "A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer", "brief_summary": "This 2 arm study will compare the safety and efficacy of oral Xeloda, or 5-fluorouracil in combination with leucovorin, in patients who have undergone surgery for colon cancer. Patients will be randomized to receive either Xeloda 1250mg/m2 po bid on days 1-14 every 21 days, or leucovorin 20mg/m2 iv + 5-fluorouracil 425mg/m2 iv daily from day 1 to day 5 every 28 days. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.", "condition": "Colorectal Cancer", "intervention_type": "Drug", "intervention_name": "Capecitabine [Xeloda]", "description": "1250mg/m2 po bid on days 1-14 every 21 days.", "arm_group_label": "Capecitabine", "criteria": "Inclusion Criteria: - adult patients 18-75 years of age; - histologically confirmed colon cancer with potentially curative resection of the tumor within 8 weeks before study initiation. Exclusion Criteria: - previous chemotherapy", "gender": "All", "minimum_age": "18 Years", "maximum_age": "75 Years", "healthy_volunteers": "No", "id": "NCT00009737.xml"}